BIAF

Business Context and Reporting Period

Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2024
Business Overview: The Company develops noninvasive diagnostics for early-stage lung cancer, primarily through its proprietary test, CyPath® Lung. Operations are conducted through two segments: Diagnostic R&D and Laboratory Services (via subsidiary Precision Pathology Laboratory Services, LLC, acquired in September 2023). The Company is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased significantly to $2.35 million for the three months ended September 30, 2024, compared to $298,484 in the same period in 2023. This 687% increase is primarily driven by the consolidation of the Precision Pathology Laboratory Services (PPLS) acquired in September 2023, which added patient service fees, histology fees, and medical director fees.
• Operating Expenses: Total operating expenses rose to $4.32 million (Q3 2024) from $2.59 million (Q3 2023). Direct costs and expenses surged by 1,828% due to the inclusion of full laboratory operations. Selling, general, and administrative (SG&A) expenses increased 17% due to added personnel and support services for commercialization.
• Net Loss: Despite revenue growth, the net loss for Q3 2024 was $2.0 million, a slight improvement from the $2.3 million loss in Q3 2023. For the nine-month period, the net loss widened to $6.1 million from $5.6 million in the prior year.
• Liquidity: Cash and cash equivalents decreased from $2.82 million at December 31, 2023, to $0.76 million at September 30, 2024, reflecting a net cash outflow from operations of $5.6 million for the nine-month period.

Guidance, Outlook, and Risks

• Going Concern: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for at least 12 months following the issuance of the report. Based on cash on hand at September 30, 2024, operations are expected to be supported only through March 2025 without additional funding.
• Recent Financing (Subsequent Event): On October 21, 2024, the Company completed a registered direct offering and concurrent private placement, raising approximately $2.3 million in gross proceeds. This extends the runway but does not eliminate the need for future capital.
• Commercialization Milestones:
  • October 9, 2024: CyPath® Lung was added to the U.S. Federal Supply Schedule, providing access to the Veterans Health Administration and Military Health System.
  • October 30, 2024: The Japan Patent Office issued a patent for the CyPath® Lung diagnostic method.
• Risks: Key risks include the inability to raise additional capital, dependence on third-party payers for revenue collection, regulatory hurdles for FDA approval (seeking De Novo classification), and the high cost of clinical trials and commercialization.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $2.3 million raised in October 2024 to cover operating expenses through March 2025 and the timeline for the next capital raise.
• Revenue Quality: Assess the sustainability of the revenue spike from the PPLS acquisition and the specific contribution of the CyPath® Lung test versus general pathology services.
• Accounts Receivable: Review the $1.33 million in accounts receivable and the impact of the billing provider transition on collection cycles and cash flow.
• Dilution: Evaluate the impact of outstanding warrants (approx. 9.6 million) and recent equity issuances on future share count and per-share value.
• Regulatory Path: Monitor progress toward FDA De Novo classification for CyPath® Lung, which is critical for broader market adoption beyond the current Laboratory Developed Test (LDT) status.